Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB | BSE: 539524 | ISIN: INE600L01024 | Industry: Healthcare Services
| Expensive Performer
2772.6000 -1.80 (-0.06%)
NSE May 12, 2025 09:41 AM
Volume: 11,410
 

2772.60
-0.06%
Geojit BNP Paribas
The company's growth in COVID business, strong brand recall, gradual unlock of cities should support growth in upcoming quarters. Given the limited upside potential we downgrade our rating to HOLD with a revised target price of Rs. 1,995 based on 53x FY22E EPS. COVID-19 tests contribute to the top line DLPL's Q1FY21 top line went down 20.6% YoY to Rs. 266cr severely impacted by COVID-19 and subsequent lock down impacting the revenue in April (-61% YoY) and May (-12% YoY), however some respite was seen in June (+14% YoY) when cities were...
Emkay increased Buy price target of Dr. Lal Pathlabs Ltd. to 3100.0 on 26 Apr, 2025.
More from Dr. Lal Pathlabs Ltd.
Recommended